Loading
A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, completed.
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer is a phase 2 interventional study registered as NCT02659514 by Spectrum Pharmaceuticals, Inc, with 67 participants recorded, started 2016-02-22 and reaching its primary completion in 2020-03-11. Interventions recorded: Poziotinib. Conditions recorded: Breast Cancer.
Linked to the drug Poziotinib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
67 enrolled.
95% CI 14.7 to 49.4; Figures from the ClinicalTrials.gov results section (first posted 2022-02-10), not from a publication · 95% CI 13.8 to 50.2
Source95% CI 1.5 to 5.6; Figures from the ClinicalTrials.gov results section (first posted 2022-02-10), not from a publication · 95% CI 1.8 to 7.4
SourceShares Poziotinib, Spectrum Pharmaceuticals, Breast cancer (all types) and the tag pipeline.
Shares Poziotinib, Spectrum Pharmaceuticals, Breast cancer (all types) and the tag pipeline.
Shares Spectrum Pharmaceuticals and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.